Cargando…
RNA Vaccines in Cancer Treatment
The Cancer Report from the World Health Organization states that in the year 2000 12% of all death cases worldwide were caused by cancer. In the western world, the cancer death rates are often devastating, being at about 25%. This fact stresses the urgency to find effective cures against malignant d...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896711/ https://www.ncbi.nlm.nih.gov/pubmed/20625504 http://dx.doi.org/10.1155/2010/623687 |
_version_ | 1782183386102628352 |
---|---|
author | Bringmann, Anita Held, Stefanie Andrea Erika Heine, Annkristin Brossart, Peter |
author_facet | Bringmann, Anita Held, Stefanie Andrea Erika Heine, Annkristin Brossart, Peter |
author_sort | Bringmann, Anita |
collection | PubMed |
description | The Cancer Report from the World Health Organization states that in the year 2000 12% of all death cases worldwide were caused by cancer. In the western world, the cancer death rates are often devastating, being at about 25%. This fact stresses the urgency to find effective cures against malignant diseases. New approaches in the treatment of cancer focus on the development of immunotherapies to fight the disease. Besides other methods, the usage of tumor-specific RNA as part of vaccines is investigated lately. RNA, administered alone or used for transfection of dendritic cells, shows several advantages as a vaccine including feasibility, applicability, safeness, and effectiveness when it comes to the generation of immune responses. This review concentrates on results from in vitro experiments and recent trials using RNA vaccines to present an overview about this specific strategy. |
format | Text |
id | pubmed-2896711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-28967112010-07-12 RNA Vaccines in Cancer Treatment Bringmann, Anita Held, Stefanie Andrea Erika Heine, Annkristin Brossart, Peter J Biomed Biotechnol Review Article The Cancer Report from the World Health Organization states that in the year 2000 12% of all death cases worldwide were caused by cancer. In the western world, the cancer death rates are often devastating, being at about 25%. This fact stresses the urgency to find effective cures against malignant diseases. New approaches in the treatment of cancer focus on the development of immunotherapies to fight the disease. Besides other methods, the usage of tumor-specific RNA as part of vaccines is investigated lately. RNA, administered alone or used for transfection of dendritic cells, shows several advantages as a vaccine including feasibility, applicability, safeness, and effectiveness when it comes to the generation of immune responses. This review concentrates on results from in vitro experiments and recent trials using RNA vaccines to present an overview about this specific strategy. Hindawi Publishing Corporation 2010 2010-06-01 /pmc/articles/PMC2896711/ /pubmed/20625504 http://dx.doi.org/10.1155/2010/623687 Text en Copyright © 2010 Anita Bringmann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Bringmann, Anita Held, Stefanie Andrea Erika Heine, Annkristin Brossart, Peter RNA Vaccines in Cancer Treatment |
title | RNA Vaccines in Cancer Treatment |
title_full | RNA Vaccines in Cancer Treatment |
title_fullStr | RNA Vaccines in Cancer Treatment |
title_full_unstemmed | RNA Vaccines in Cancer Treatment |
title_short | RNA Vaccines in Cancer Treatment |
title_sort | rna vaccines in cancer treatment |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896711/ https://www.ncbi.nlm.nih.gov/pubmed/20625504 http://dx.doi.org/10.1155/2010/623687 |
work_keys_str_mv | AT bringmannanita rnavaccinesincancertreatment AT heldstefanieandreaerika rnavaccinesincancertreatment AT heineannkristin rnavaccinesincancertreatment AT brossartpeter rnavaccinesincancertreatment |